Serious adverse events and death associated with treatment using long-acting β-agonists

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Two very large, randomized, double-blind clinical trials performed in the United Kingdom and in the United States have suggested that addition of salmeteräÊ to usual asthma therapy is associated with a significant increase in the incidence of serious adverse events and asthma-related deaths compared with addition of albuterol or placebo to usual therapy in the same type of patients. These results prompted the United States Food and Drug Administration (FDA) to issue a stern warning regarding these potential adverse effects and to advise that long-acting β-agonists (LABAs) should not used as first-line therapy for the treatment of asthma. Two potential explanations have been proposed for these unexpected adverse effects. It has been suggested that more than a direct pharmacological effect of LABAs, these adverse events result from inadequate concomitant use of inhaled corticosteroids in subjects treated with these medicines. However, a detailed analysis of the results of the two large trials did not provide definitive conclusions regarding the potential protective role of inhaled corticosteroids. A second explanation, which the author here considers more plausible, is that a small group of patients with asthma develop idiosyncratic responses to LABAs, and common or rare variants in the genes that encode for proteins associated with the pharmacological response to these medicines are strongly suspected to predispose for these unusual deleterious responses. Until the biological mechanisms involved are better understood, efforts should be made to confine the use of LABAs to those patients who really need them.

Original languageEnglish (US)
Pages (from-to)269-278
Number of pages10
JournalClinical Reviews in Allergy and Immunology
Volume31
Issue number2-3
DOIs
StatePublished - Oct 2006

Fingerprint

Asthma
Adrenal Cortex Hormones
Pharmacology
Albuterol
United States Food and Drug Administration
Therapeutics
Placebos
Clinical Trials
Incidence
Proteins

Keywords

  • Adverse events
  • Asthma
  • Exacerbations
  • Gene
  • Inhaled corticosteroids
  • LABAs
  • Polymorphisms

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Serious adverse events and death associated with treatment using long-acting β-agonists. / Martinez, Fernando.

In: Clinical Reviews in Allergy and Immunology, Vol. 31, No. 2-3, 10.2006, p. 269-278.

Research output: Contribution to journalArticle

@article{9735e6d445854467a21cb465ed6ae1c2,
title = "Serious adverse events and death associated with treatment using long-acting β-agonists",
abstract = "Two very large, randomized, double-blind clinical trials performed in the United Kingdom and in the United States have suggested that addition of salmeter{\"a}{\^E} to usual asthma therapy is associated with a significant increase in the incidence of serious adverse events and asthma-related deaths compared with addition of albuterol or placebo to usual therapy in the same type of patients. These results prompted the United States Food and Drug Administration (FDA) to issue a stern warning regarding these potential adverse effects and to advise that long-acting β-agonists (LABAs) should not used as first-line therapy for the treatment of asthma. Two potential explanations have been proposed for these unexpected adverse effects. It has been suggested that more than a direct pharmacological effect of LABAs, these adverse events result from inadequate concomitant use of inhaled corticosteroids in subjects treated with these medicines. However, a detailed analysis of the results of the two large trials did not provide definitive conclusions regarding the potential protective role of inhaled corticosteroids. A second explanation, which the author here considers more plausible, is that a small group of patients with asthma develop idiosyncratic responses to LABAs, and common or rare variants in the genes that encode for proteins associated with the pharmacological response to these medicines are strongly suspected to predispose for these unusual deleterious responses. Until the biological mechanisms involved are better understood, efforts should be made to confine the use of LABAs to those patients who really need them.",
keywords = "Adverse events, Asthma, Exacerbations, Gene, Inhaled corticosteroids, LABAs, Polymorphisms",
author = "Fernando Martinez",
year = "2006",
month = "10",
doi = "10.1385/CRIAI:31:2:269",
language = "English (US)",
volume = "31",
pages = "269--278",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "2-3",

}

TY - JOUR

T1 - Serious adverse events and death associated with treatment using long-acting β-agonists

AU - Martinez, Fernando

PY - 2006/10

Y1 - 2006/10

N2 - Two very large, randomized, double-blind clinical trials performed in the United Kingdom and in the United States have suggested that addition of salmeteräÊ to usual asthma therapy is associated with a significant increase in the incidence of serious adverse events and asthma-related deaths compared with addition of albuterol or placebo to usual therapy in the same type of patients. These results prompted the United States Food and Drug Administration (FDA) to issue a stern warning regarding these potential adverse effects and to advise that long-acting β-agonists (LABAs) should not used as first-line therapy for the treatment of asthma. Two potential explanations have been proposed for these unexpected adverse effects. It has been suggested that more than a direct pharmacological effect of LABAs, these adverse events result from inadequate concomitant use of inhaled corticosteroids in subjects treated with these medicines. However, a detailed analysis of the results of the two large trials did not provide definitive conclusions regarding the potential protective role of inhaled corticosteroids. A second explanation, which the author here considers more plausible, is that a small group of patients with asthma develop idiosyncratic responses to LABAs, and common or rare variants in the genes that encode for proteins associated with the pharmacological response to these medicines are strongly suspected to predispose for these unusual deleterious responses. Until the biological mechanisms involved are better understood, efforts should be made to confine the use of LABAs to those patients who really need them.

AB - Two very large, randomized, double-blind clinical trials performed in the United Kingdom and in the United States have suggested that addition of salmeteräÊ to usual asthma therapy is associated with a significant increase in the incidence of serious adverse events and asthma-related deaths compared with addition of albuterol or placebo to usual therapy in the same type of patients. These results prompted the United States Food and Drug Administration (FDA) to issue a stern warning regarding these potential adverse effects and to advise that long-acting β-agonists (LABAs) should not used as first-line therapy for the treatment of asthma. Two potential explanations have been proposed for these unexpected adverse effects. It has been suggested that more than a direct pharmacological effect of LABAs, these adverse events result from inadequate concomitant use of inhaled corticosteroids in subjects treated with these medicines. However, a detailed analysis of the results of the two large trials did not provide definitive conclusions regarding the potential protective role of inhaled corticosteroids. A second explanation, which the author here considers more plausible, is that a small group of patients with asthma develop idiosyncratic responses to LABAs, and common or rare variants in the genes that encode for proteins associated with the pharmacological response to these medicines are strongly suspected to predispose for these unusual deleterious responses. Until the biological mechanisms involved are better understood, efforts should be made to confine the use of LABAs to those patients who really need them.

KW - Adverse events

KW - Asthma

KW - Exacerbations

KW - Gene

KW - Inhaled corticosteroids

KW - LABAs

KW - Polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=33751348016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751348016&partnerID=8YFLogxK

U2 - 10.1385/CRIAI:31:2:269

DO - 10.1385/CRIAI:31:2:269

M3 - Article

VL - 31

SP - 269

EP - 278

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 2-3

ER -